Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study (NCT07518160) | Shanghai Junshi Bioscience Co., Ltd. | 2026-04-21 |
Track Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations automatically
Every clearance here is in the API, with alerts when new ones post.